MedTrace Logo

Health Economics Evaluation of Catheter Ablation Versus Drug Therapy in Atrial Fibrillation (AF) in China

NCT01878981 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2019-11-14

No results posted yet for this study

Summary

To generate real world evidence to compare clinical outcomes and patient health-related quality of life, resulting from catheter ablation therapy with clinical outcome and patient health-related quality of life resulting from drug therapy in China. An economic model will be constructed, and using the clinical events evidence collected in this study, and China long-term disease progression and local disease cost data to perform a cost-effectiveness evaluation of Catheter Ablation versus Drug Therapy in AF (Paroxysmal plus Persistent AF) patients.

Conditions

Sponsors & Collaborators

  • Johnson & Johnson Medical, China

    lead INDUSTRY

Principal Investigators

  • Changsheng Ma, doctor · Beijing Anzhen Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2013-11-23
Completion
2013-11-23

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01878981 on ClinicalTrials.gov